ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (CNS) disorders. All of ACADIA's product candidates emanate from internal discoveries. We believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies.

ACADIAÍs history is rooted in science and strong leadership in CNS research. Our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. Since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders.

ACADIA is headquartered in San Diego. The city represents the second largest biotechnology industry cluster in the United States, home to over 400 companies, as well as the Salk Institute for Biological Studies and the Scripps Research Institute.